$9.71
0.00% (Daily)
Market Cap
$39.28M
Revenue
$8.30M
Rank by MCap
#1153
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Thane Wettig
Headquarters
San Francisco, CA
Employees
225
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplast...
Loading chart…